1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Canada Pharmaceutical Industry

Canada Pharmaceutical Industry

  • February 2016
  • -
  • Aruvian's R'search
  • -
  • 160 pages

The Canadian pharmaceutical market is the eighth largest in the world, accounting for about two percent of the world market by sales. Canada also has the fourth fastest growing pharmaceutical industry after China, the US and Spain and has shown a steady growth trend. The Canadian pharmaceutical industry is gradually becoming more favorable towards generic drugs rather than branded drugs.

Although the pharmaceutical industry claims to be a high-risk business, year after year drug companies enjoy higher profits than any other industry. The pharmaceutical industry is one of the most innovative and profitable industries in Canada. This industry is composed of brand-name drug companies (which include biopharmaceutical companies) and generic drug companies. Both segments produce prescription and non-prescription drugs

Aruvian Research’s report – Canada Pharmaceutical Industry – explores the Canadian Pharmaceutical Industry landscape from the basics to the issues facing the industry today. The report delves in to the TRIPS agreement and the effect of the agreement on the Canadian pharmaceutical industry, growth trends in the industry, competition in the industry, etc.

The report also analyzes the Canadian pharmaceutical industry through two frameworks – a SWOT analysis and a Porter’s Five Forces Business Strategy analysis. The report also looks at strategies for market entry, the role of R&D in the Canadian Pharmaceutical Industry, and the role of the government in the industry.

Complete with a comprehensive section on the clinical trials, market investment opportunities going on in the Canadian pharmaceutical industry, Aruvian’s latest research is a collection of all you need to know about Canada’s Pharmaceutical Industry.

Table Of Contents

Canada Pharmaceutical Industry
A. Executive Summary

B. Introduction to the Industry
B.1 Industry Definition
B.2 Canada's Pharmaceutical Sector - SWOT Framework Analysis
B.2.1 Strengths to Build On
B.2.2 Weaknesses to Overcome
B.2.3 Opportunities to Exploit
B.2.4 Threats to Overcome
B.3 Industry Overview
B.4 Size and Structure of the Industry
B.5 Industry Growth by Value Analysis
B.6 Market Segments
B.7 Canadian Drug Sales
B.8 Competition in the Industry
B.9 Market Share Analysis
B.10 Major Growth Factors
B.11 Canada's Pharmaceutical Industry's Cost Advantage
B.12 Clinical Trials
B.13 Market Access

C. OTC Pharmaceuticals in Canada
C.1 Industry Definition
C.2 Industry Overview
C.3 Industry Growth by Value Analysis
C.4 Market Segments
C.5 Competition in the Industry
C.6 Market Share
C.7 Distribution Channels
C.8 Industry Forecast

D. Generics Market in Canada
D.1 Industry Definition
D.2 Industry Overview
D.3 Industry Growth by Value Analysis
D.4 Industry Growth by Volume Analysis
D.5 Geographical Segmentation
D.6 Competition in the Industry
D.7 Industry Forecast

E. Regulatory Developments and Trends in the Industry

F. Porter's Five Forces Strategy Analysis of Canada's Pharmaceutical Industry
F.1 Bargaining Power of Buyers
F.2 Bargaining Power of Suppliers
F.3 Competitive Rivalry in the Industry
F.4 Threat of New Entrants
F.5 Threat of Substitutes
F.6 Conclusion

G. Pricing and Reimbursement System in the Industry

H. Re-import Policies for Drugs

I. Pharmaceutical RandD in Canada

J. TRIPS and Canada
J.1 Doha Declaration
J.2 Canadian Legislation
J.3 Humanitarian Contributions of Canadian Companies

K. Industry Forecast

L. Major Industry Players
L.1 Allergan Plc
L.1.1 Corporate Profile
L.1.2 Business Segment Analysis
L.1.3 Financial Analysis
L.1.4 SWOT Analysis
L.2 AstraZeneca PLC
L.2.1 Corporate Profile
L.2.2 Business Segment Analysis
L.2.3 Financial Analysis
L.2.4 SWOT Analysis
L.3 GlaxoSmithKline Plc
L.3.1 Corporate Profile
L.3.2 Business Segment Analysis
L.3.3 Financial Analysis
L.3.4 SWOT Analysis
L.4 Johnson and Johnson
L.4.1 Corporate Profile
L.4.2 Business Segment Analysis
L.4.3 Financial Analysis
L.4.4 SWOT Analysis
L.5 Mylan N.V.
L.5.1 Corporate Profile
L.5.2 Business Segment Analysis
L.5.3 Financial Analysis
L.5.4 SWOT Analysis
L.6 Pfizer Inc.
L.6.1 Corporate Profile
L.6.2 Business Segment Analysis
L.6.3 Financial Analysis
L.6.4 SWOT Analysis
L.7 Sanofi SA
L.7.1 Corporate Profile
L.7.2 Business Segment Analysis
L.7.3 Financial Analysis
L.7.4 SWOT Analysis
L.8 Teva Pharmaceutical Industries Limited
L.8.1 Corporate Profile
L.8.2 Business Segment Analysis
L.8.3 Financial Analysis
L.8.4 SWOT Analysis
L.9 Apotex Holdings
L.10 Sandoz International GmbH

M. Glossary of Terms

List of Figures

Figure 1: Average Profit Margins for Selected Industries (2009-2014)
Figure 2: Distribution of Pharmaceutical RandD Expenditures by Geographic Areas - 2014
Figure 3: Growth in the Canadian Pharmaceuticals Market by Value (in USD Billion), 2010-2014
Figure 4: Share of the Canadian Pharmaceutical Industry in the Americas (%), 2014
Figure 5: Market Share Analysis of the Canadian Pharmaceutical Industry (%), 2014
Figure 6: Growth of the Canadian OTC Pharmaceutical Market in Value Terms (in USD Million), 2010-2014
Figure 7: Canadian OTC Pharma Market Segmentation (%), 2014
Figure 8: Share of Canada's OTC Market in the Americas (%), 2014
Figure 9: Market Share of the Canadian OTC Pharmaceutical Industry (%), 2014
Figure 10: Leading Distribution Channels in Canada's OTC Pharmaceutical Industry (%), 2014
Figure 11: Forecast of the Canadian OTC Pharmaceutical Industry (in USD Million), 2014-2019
Figure 12: Growth of the Canadian Generics Industry by Value (in USD Million), 2010-2014
Figure 13: Growth of the Canadian Generics Industry by Volumes (in Percentage of Total Pharma Industry Volume), 2010-2014
Figure 14: Share of Canada in the Americas Generics Industry (%), 2014
Figure 15: Forecast of the Canadian Generics Industry (in USD Million), 2014-2019
Figure 16: Volume Forecast of the Canadian Generics Industry (in Percentage of Total Pharmaceutical Industry Volume), 2014-2019
Figure 17: Porter's Five Forces Analysis of the Canadian Pharmaceutical Industry
Figure 18: Bargaining Power of Buyers in the Canadian Pharmaceutical Industry
Figure 19: Bargaining Power of Suppliers in the Canadian Pharmaceutical Industry
Figure 20: Competitive Rivalry in the Canadian Pharmaceutical Industry
Figure 21: Threat of New Entrants to the Canadian Pharmaceutical Industry
Figure 22: Threat of Substitutes to the Canadian Pharmaceutical Industry
Figure 23: Forecast of the Canadian Pharmaceutical Industry (in USD Billion), 2014-2019

List of Tables

Table 1: Growth in the Canadian Pharmaceuticals Market by Value (in USD Billion), 2010-2014
Table 2: Canada Pharmaceuticals Market Segmentation % Share, by Value, 2014
Table 3: Share of the Canadian Pharmaceutical Industry in the Americas (in USD Billion and %), 2014
Table 4: Health Expenditure Indicators
Table 5: International Cost Comparison of the Pharmaceutical Industry (US = 100)
Table 6: Growth of the Canadian OTC Pharmaceutical Market in Value Terms (in USD Million), 2010-2014
Table 7: Canadian OTC Pharma Market Segmentation (in USD Million and %), 2014
Table 8: Share of Canada's OTC Market in the Americas (in USD Million and %), 2014
Table 9: Forecast of the Canadian OTC Pharmaceutical Industry (in USD Million), 2014-2019
Table 10: Growth of the Canadian Generics Industry by Value (in USD Million), 2010-2014
Table 11: Growth of the Canadian Generics Industry by Volumes (in Percentage of Total Pharma Industry Volume), 2010-2014
Table 12: Share of Canada in the Americas Generics Industry (in USD Million and %), 2014
Table 13: Forecast of the Canadian Generics Industry (in USD Million), 2014-2019
Table 14: Volume Forecast of the Canadian Generics Industry (in Percentage of Total Pharmaceutical Industry Volume), 2014-2019
Table 15: Innovators' Reasons for Cooperating
Table 16: Forecast of the Canadian Pharmaceutical Industry (in USD Billion), 2014-2019
Table 17: Key Financials of Allergan Plc (in USD Million), 2014-2015
Table 18: Key Financials of AstraZeneca (in USD Million), 2014-2015
Table 19: Key Financials of GSK (in USD Million), 2014-2015
Table 20: Key Financials of Johnson and Johnson (in USD Million), 2014-2015
Table 21: Key Financials of Mylan N.V. (in USD Million), 2014-2015
Table 22: Key Financials of Pfizer Inc. (in USD Million), 2014-2015
Table 23: Key Financials of Sanofi SA (in USD Million), 2014-2015
Table 24: Key Financials of Teva Pharmaceutical Industries (in USD Million), 2014-2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.